Plain-English translation of NCT06962020 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This study is comparing two biologic medications—IFX and VDZ—to see which one works better as a first-line treatment for moderate-to-severe ulcerative colitis. Researchers will follow patients over time to understand how well each medication works and what factors might affect how well it works for different people.
Doctors currently use both of these medications to treat severe ulcerative colitis, but it's not always clear which one should be tried first or which one works better for individual patients. This study aims to answer that question by observing real patients in actual clinical practice.
You likely qualify if…
You likely don't qualify if…
If you join this study, you will receive one of the two biologic medications as your first-line treatment. You'll receive regular doses of the medication over 3 treatment cycles, then continue with the same medication or switch to the other one based on how well it's working. Throughout the study, you'll have regular clinic visits and blood tests to track how your ulcerative colitis responds to treatment and identify what factors might influence how well the medication works for you.
AI-generated summary from trial data · Jun 2, 2026 · Not medical advice
China